Subscribe To
Codexis (cdxs) transfers leasing rights to vaxcyte, stock up
Codexis (CDXS) transfers the leasing rights of its San Carlos, CA location to vaxcyte to focus on techn...
September 11, 2023, 9:46 am
Strong financials and pipeline position vaxcyte for success
vaxcyte, Inc. is a clinical-stage vaccine company developing high-fidelity vaccines for bacterial disea...
August 17, 2023, 6:34 pm
Wall street analysts think vaxcyte, inc. (pcvx) could surge 33.33%: read this before placing a bet
The average of price targets set by Wall Street analysts indicates a potential upside of 33.3% in vaxcyte...
May 29, 2023, 11:05 am
vaxcyte: positive phase 2 results elevate confidence in vax-24's potential
vaxcyte is emerging as a leader in vaccine innovation, leveraging high-fidelity vaccines to combat bact...
May 17, 2023, 8:20 am
vaxcyte announces closing of $575 million public offering including full exercise of underwriters’ option to purchase additional shares
SAN CARLOS, Calif., April 21, 2023 (GLOBE NEWSWIRE) — vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage ...
April 21, 2023, 9:25 pm
vaxcyte announces pricing of $500 million public offering
SAN CARLOS, Calif., April 19, 2023 (GLOBE NEWSWIRE) — vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage ...
April 19, 2023, 4:26 am
vaxcyte (pcvx) up on pneumococcal conjugate vaccine data
vaxcyte (PCVX) announces positive results from the mid-stage study of its 24-Valent pneumococcal conjug...
April 18, 2023, 2:28 pm
Still 50% upside to go, wall street is getting vaxcyte right
When SVB Securities analyst David Risinger reiterated his bullish opinion on vaxcyte, Inc. (NASDAQ: PCV...
April 18, 2023, 8:36 am
vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f
SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) — vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage ...
April 16, 2023, 9:00 pm
vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f
SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) — vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage ...
April 16, 2023, 9:00 pm
vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f
SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) — vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage ...
April 16, 2023, 9:00 pm
vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f
SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) — vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage ...
April 16, 2023, 9:00 pm
vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f
SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) — vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage ...
April 16, 2023, 9:00 pm
vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f
SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage v...
April 16, 2023, 5:00 pm
vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f
SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage v...
April 16, 2023, 5:00 pm
vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f
SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage v...
April 16, 2023, 5:00 pm
vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f
SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage v...
April 16, 2023, 5:00 pm
vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f
SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage v...
April 16, 2023, 5:00 pm
vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f
SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage v...
April 16, 2023, 5:00 pm
vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f
SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage v...
April 16, 2023, 5:00 pm